Gut microbiome linked to deadly lung disease
Australian researchers have shown for the first time a link between chronic obstructive pulmonary disease (COPD), an often fatal lung condition, and the gut microbiome.
Their findings, published in the journal Nature Communications, suggest that the gut may be helpful in diagnosing COPD and may also be a potential source of new therapeutic targets to help treat the chronic respiratory disorder, which is the third most common cause of death globally.
“It’s already known that the lung microbiome is a contributing factor in COPD,” said Professor Phil Hansbro, senior author of the study and Director of the Centenary UTS Centre for Inflammation.
“We wanted to see if the gut environment was also somehow involved — to determine whether the gut could act as a reliable indicator of COPD or if it was connected in some way to the development of the disease.”
In the study, the researchers compared the microbiome and metabolite profiles of stool samples from COPD patients with healthy individuals. Revealed were significant differences between the two groups.
COPD patients exhibited increased levels of the bacteria Streptococcus and Lachnospiraceae in their stool samples. Also identified in individuals with COPD was a unique metabolite signature, formed by the chemical by-products of the metabolic process.
“Our research indicates that the gut of COPD patients is notably different from healthy individuals,” said first author Dr Kate Bowerman, from The University of Queensland.
“This suggests that stool sampling and analysis could be used to non-invasively diagnose and monitor for COPD.”
The researchers believe that the altered gut microbiome found in COPD patients could also support the gut as a potential target for new treatments. Prof Hansbro explained, “The ‘gut–lung axis’ describes the common immune system of the lung and gastrointestinal tract. This means that activity in the gut can impact activity in the lung. Our COPD findings suggest that the gut microbiome should now also be considered when looking for new therapeutic targets to help treat lung disease.”
Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
